The role of biomaterials in stem cell-based regenerative medicine
Posted: 6 June 2018 | Laura Goldie - Head of Technical Services - Biogelx Ltd. | No comments yet
Despite their vast therapeutic potential in such areas as cell therapy and tissue engineering, stem cells have yet to live up to their original hype and demonstrate widespread clinical success.
There is only one FDA-approved stem cell treatment, that being the use of blood-forming stem cells derived from cord blood, which have been used for the treatment of leukaemia for decades. Despite the recent rapid advances within the field of stem cell research, and an ever-growing population of researchers in academia, biotech, and the pharmaceutical industry focused on the development of stem cell-based treatments for a range of conditions, there has been a limited progression of such research from bench to bedside.
The rest of this content is restricted - login or subscribe free to access
Thank you for visiting our website. To access this content in full you'll need to login. It's completely free to subscribe, and in less than a minute you can continue reading. If you've already subscribed, great - just login.
Why subscribe? Join our growing community of thousands of industry professionals and gain access to:
- quarterly issues in print and/or digital format
- case studies, whitepapers, webinars and industry-leading content
- breaking news and features
- our extensive online archive of thousands of articles and years of past issues
- ...And it's all free!